—
C+
C+ The full Closelook — membership. Open the C+ overview

Takeda Pharmaceutical Co Ltd ADR (TAK) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Takeda Pharmaceutical Co Ltd ADR

TAK in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Takeda researches, develops, manufactures and markets pharmaceutical products, and also out-licenses some of its science to other firms. Its portfolio spans gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines and neuroscience, sold under brand names such as Entyvio and Vyvanse. It works with a wide network of licensing and collaboration partners across drug development. It is headquartered in Chuo, Japan, and sells its products worldwide.
Where it sits in the stack
Takeda holds no seat in our AI build-out index; it sits in the Healthcare sector of the diary's wider universe, grouped with other scored drugmakers and biotech names rather than with any semiconductor or data-centre layer.
Who it is priced against
Closelook's peer group for Takeda is scored healthcare names sharing its sector and country — argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics; the market also names Pfizer as a comparison.
Why Closelook tracks it
Takeda carries a Closelook score, a composite drawn across several modules, with valuation reading strongest and quality reading weakest; it has no index seats and no diary quotes on file.
What the diary watches
The diary watches whether the weak quality reading firms up, and whether the licensing pipeline with its many partners converts into approved products.

Takeda Pharmaceutical Co Ltd ADR (TAK) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 50/100 composite (momentum 69, quality 38, valuation 81) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for TAK, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 7 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against TAK on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 3.33%, semi-annual · buybacks 51.6 bn USD in FY2026

Dividends and capital return

What TAK pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.63 USD per share · a 3.33% yield on the 2026-09-18 close 2 distributions, paid twice a year 2026-09-18
  • Change on the year +86.0% against the prior twelve months prior twelve months 0.34 USD per share
  • Last distribution 0.31 USD per share as the price series records it, within days of the ex-date 2026-03-31
  • By calendar year 2025: 0.66 USD (partial) · 2026: 0.31 USD to date first distribution recorded in the three-year window: 2025-03-31
  • Dividends paid, FY2026 311.9 bn USD 80% of earnings
  • Buybacks, FY2026 51.6 bn USD 86.4% of today's market value
  • Share count −0.2% in FY2026 72.8 bn USD of stock-based compensation in the year
  • Capital returned 363.5 bn USD · 58% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in US: +1.8% week · −4.1% month · +13.2% quarter · +8.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Takeda Pharmaceutical Co Ltd ADR (TAK)?

Takeda Pharmaceutical Co Ltd ADR trades as TAK on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is TAK in a Closelook index?

Not currently — Takeda Pharmaceutical Co Ltd ADR is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Takeda Pharmaceutical Co Ltd ADR's Closelook composite score?

50 out of 100, with momentum 69, quality 38 and valuation 81 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does TAK trade against its moving averages?

Uptrend stack intact: Trades +7% vs the 50-day and +12.3% vs the 200-day average, 1% below the 52-week high and +48.1% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Takeda Pharmaceutical Co Ltd ADR do?

Takeda researches, develops, manufactures and markets pharmaceutical products, and also out-licenses some of its science to other firms. Its portfolio spans gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines and neuroscience, sold under brand names such as Entyvio and Vyvanse. It works with a wide network of licensing and collaboration partners across drug development. Closelook's peer group for Takeda is scored healthcare names sharing its sector and country — argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics; the market also names Pfizer as a comparison.

Where does Takeda Pharmaceutical Co Ltd ADR sit in the AI build-out?

Takeda holds no seat in our AI build-out index; it sits in the Healthcare sector of the diary's wider universe, grouped with other scored drugmakers and biotech names rather than with any semiconductor or data-centre layer. Takeda carries a Closelook score, a composite drawn across several modules, with valuation reading strongest and quality reading weakest; it has no index seats and no diary quotes on file.

Does Takeda Pharmaceutical Co Ltd ADR pay a dividend?

Takeda Pharmaceutical Co Ltd ADR has paid 0.63 USD per share over the last twelve months, paid twice a year, a trailing yield of 3.33% on the 2026-09-18 close; the last distribution recorded in the price series was 0.31 USD on 2026-03-31. In fiscal 2026 the company paid 311.9 bn USD in dividends and bought back 51.6 bn USD of its own shares, 58% of that year’s free cash flow. The share count fell 0.2% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for TAK, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.